Silva Taís C, Godoy-Silva Julia, Amaro Monique C, Silva-Silva João V, Doring Thiago H, Ferreira Leonardo L G, Andricopulo Adriano D, de Moraes Josué
Research Center on Neglected Diseases, Guarulhos University, Guarulhos 07023-070, SP, Brazil.
Laboratory of Medicinal and Computational Chemistry (LQMC), Institute of Physics of Sao Carlos (IFSC), University of Sao Paulo (USP), Sao Carlos 13563-120, SP, Brazil.
Pharmaceuticals (Basel). 2025 Jul 2;18(7):997. doi: 10.3390/ph18070997.
: Parasitic worm infections remain among the most prevalent and neglected health issues worldwide, affecting both humans and animals. Toxocariasis, caused by spp., is a widespread zoonosis with significant public health and economic implications. Current anthelmintic treatments show limited efficacy, particularly against tissue-migrating larvae, underscoring the urgent need for new therapeutic options. This study aimed to evaluate the anthelmintic potential of H antihistamines as repurposed drug candidates against . : Twenty-two H antihistamines were screened for larvicidal activity against infective third-stage (L3) larvae of . Larval motility and morphology were assessed, and compounds with the highest efficacy were further investigated using density functional theory (DFT) to explore their electronic properties. Molecular docking simulations were also performed to predict interactions with β-tubulin. : Promethazine and rupatadine exhibited significant larvicidal effects, surpassing albendazole in reducing larval motility and inducing a distinct contorted morphology not observed in control or albendazole-treated larvae. DFT analyses suggested a strong electron-acceptor capacity, indicating a potential redox-based mechanism of action. Docking studies revealed favorable binding to the colchicine site of β-tubulin. : This is the first report of larvicidal activity of antihistamines against , supporting their potential as repurposed therapeutic agents for the treatment of zoonotic helminthiases, particularly those caused by tissue-migrating nematodes.
寄生虫感染仍然是全球最普遍且被忽视的健康问题之一,影响着人类和动物。由蛔虫属物种引起的弓蛔虫病是一种广泛传播的人畜共患病,具有重大的公共卫生和经济影响。目前的驱虫治疗效果有限,尤其是对组织内移行幼虫,这凸显了对新治疗方案的迫切需求。本研究旨在评估H1抗组胺药作为重新利用的候选药物对抗弓蛔虫的驱虫潜力。对22种H1抗组胺药进行了针对弓蛔虫感染性三期(L3)幼虫的杀幼虫活性筛选。评估了幼虫的活力和形态,并使用密度泛函理论(DFT)对疗效最高的化合物进行了进一步研究,以探索其电子性质。还进行了分子对接模拟,以预测与弓蛔虫β-微管蛋白的相互作用。异丙嗪和鲁帕他定表现出显著的杀幼虫作用,在降低幼虫活力方面超过阿苯达唑,并诱导出对照或阿苯达唑处理的幼虫中未观察到的明显扭曲形态。DFT分析表明其具有很强的电子受体能力,表明可能存在基于氧化还原的作用机制。对接研究显示与弓蛔虫β-微管蛋白的秋水仙碱结合位点有良好的结合。这是关于抗组胺药对弓蛔虫杀幼虫活性的首次报道,支持了它们作为重新利用的治疗药物用于治疗人畜共患蠕虫病,特别是由组织内移行线虫引起的蠕虫病的潜力。